MI-EATON-VEHICLE-GROUP
10.8.2021 17:01:13 CEST | Business Wire | Press release
Power management company Eaton today announced its Vehicle Group has developed a series of 48-volt technologies to assist its global on- and off-highway commercial vehicle customers transitioning from traditional 12- and 24-volt vehicle systems to systems that include 48-volt architecture. These 48-volt systems can power new, advanced energy-consuming components and can help reduce emissions and improve fuel economy and performance.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210810005722/en/
“This development comes as global vehicle manufacturers are making decisions to adopt new technologies to meet emissions regulations,” said Ben Karrer, manager, Technology Development, Eaton’s Vehicle Group. “Of the options available, 48-volt architectures are becoming more popular because they can decrease both CO2 and NOx simultaneously, which helps both our customers and the environment.”
Most vehicles have traditionally operated with a 12-volt system, but with tightening fuel economy regulations and new, advanced power-consuming components being added, increasing power needs are driving the move toward 48-volt systems.
Reduce mechanical loads and CO2 by powering systems with 48-volt architecture
Many vehicle systems today are powered directly from mechanical power generated by the engine, which runs 12-volt systems such as air conditioning and pumps. Eaton is developing 48-volt systems that include motor generators and inverters that generate 48-volt DC power for the vehicle. Eaton also produces 48-volt DC/DC converters that step power down from 48-volt vehicle architectures to power 12- and 24-volt systems.
48-volt system can heat aftertreatment catalyst to reduce NOx emissions
Collectively, new emissions regulations will reduce tailpipe NOx limits by up to 90%, accelerating the need for global engine manufacturers to employ additional emissions reduction strategies.
Eaton’s Vehicle Group is also developing power electronics for 48-volt electric catalyst heating, which provides heat directly to the vehicle’s aftertreatment system. This active heating helps catalyst components reach efficient operating temperatures faster upon engine start and maintain those temperatures during low load operation. This will be an essential strategy for reducing emissions to the levels required by future regulations.
“Forty-eight-volt power will also be used to power systems such as HVAC and the engine cooling fan, which are traditionally run by the engine,” said Karrer. “Today’s systems are not intelligent—you can’t control when they’re on or off or adjust the levels. Converting those components to electric alternatives allows you to intelligently control them and eliminate mechanical loads.”
Electrified cooling offers multiple environmental, efficiency improvements
An electrical engine cooling fan and electric air conditioning compressor are also under development. Electrifying the cooling fan provides additional benefits, as it could be reduced in size and strategically placed within the engine bay, allowing for aerodynamic design flexibility to increase fuel economy and reduce emissions.
Supercapacitors, lead-acid batteries for 48-volt system power storage
Eaton’s Vehicle Group is developing a wide range of 48-volt energy storage solutions, including lead-acid batteries and supercapacitors.
“We’re integrating various energy storage technologies into a larger storage pack including controls, fusing, and contactors,” said Karrer. “Eaton’s Electrical Components Group is our partner for supercapacitors, and we will be working with most commercial vehicle battery manufacturers for lead-acid batteries.”
Lead-acid batteries are inexpensive compared to lithium-ion packs and offer a safe and more efficient solution, with a longer lifespan when compared to existing lead-acid battery applications.
Supercapacitors are able to quickly charge and discharge at higher rates than lithium-ion batteries. While the size and weight are comparable to lithium-ion packs, supercapacitors don’t retain high levels of energy in comparison or require a liquid cooling system, and they have a longer cycle life.
This suite of technologies is an example of how Eaton is working to achieve its 2030 Sustainability Targets , which include reducing the carbon emissions from our operations by half and lowering product and supply chain emissions. Learn more about our commitment to improving the quality of life and the environment.
Eaton’s mission is to improve the quality of life and the environment through the use of power management technologies and services. We provide sustainable solutions that help our customers effectively manage electrical, hydraulic, and mechanical power – more safely, more efficiently, and more reliably. Eaton’s 2020 revenues were $17.9 billion, and we sell products to customers in more than 175 countries. We have approximately 85,000 employees. For more information, visit www.eaton.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210810005722/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release
The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom